HGSI's Albuferon for hepatitis C advancing

March 14, 2006 at 11:09 AM

ROCKVILLE, Md., March 14 (UPI) -- Human Genome Sciences said its hepatitis C treatment Albuferon showed strong anti-viral activity in phase 2 trials.

David Stump, HGSI's executive vice president of drug development, said the company's phase 3 trials could be launched by the end of the year.

In the phase 2 study, 30 percent of the patients in the lower-dose treatment groups did not have detectable levels of the hepatitis C virus at the end of treatment, or week 48. This percentage dropped to 18 percent at the 12-week follow-up. HGSI said they considered the data positive because nearly two-thirds of the study participants had failed on previous treatment regimens.

In a phase 2b trial in interferon alpha-naive patients, Albuferon showed a trend toward being comparable to Pegasys with less frequent dosing. Approximately 75 percent of patients receiving Albuferon every 2 weeks exhibited a level of hepatitis C viral load below the level of quantitation at 12 weeks, compared with 66 percent of patients receiving Pegasys at seven-day intervals.

Related UPI Stories
Latest Headlines
Trending Stories
Females with childhood ADHD at double the risk for obesity
Medicaid-paid births up in Texas since defunding Planned Parenthood
New ethics standards for DNA replacement therapies
New screening method detects all cystic fibrosis mutations
Esophageal cooling device helps doctors control body temperature